RCT: Once weekly semaglutide 2.0 mg vs. 1.0 mg in patients with type 2 diabetes – Mean change in HbA1c from baseline was −2.2 percentage points with 2.0 mg vs. −1.9 percentage points with 1.0 mg; mean change in bodyweight from baseline was −6.9 kg with 2.0 mg vs. −6.0 kg with 1.0 mg.

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial – The Lancet Endocrinology & Diabetes (link to abstract – $ for full-text)